| INTRODUC TI ONOverall, solid organ transplant (SOT) recipients have a 2-to 4-fold increased incidence rate of all types of cancer, 1,2 and a 3-to 5-fold increased rate of cancer mortality, as compared with respective rates in the general population. The burden of gynecologic malignancies among transplant recipients-including uterine, ovarian, cervical, vulvar, and vaginal cancers-is of particular concern because women now live longer after transplantation due to advances in immunosuppressive therapies, and malignancy has become a leading cause of death among SOT recipients. 3,4 Although gynecologic cancers are functionally related to reproduction, they encompass diverse tumor biology and equally diverse variation in risk factors and epidemiologic characteristics. Management of gynecologic cancers among SOT recipients is further complicated by the necessity of maintenance immunosuppression to prevent and/or treat graft rejection, which confers an increased risk of infection and malignancy after transplantation.Two of the gynecologic cancers, uterine and ovarian cancers, are primarily hormone-regulated cancers. 5 The other three gynecologic cancers-cervical, vulvar, and vaginal cancers, and their high-grade precursor lesions that require treatment to avoid progression-are often related to persistent high-risk human papillomavirus (HPV) infection in the setting of immune suppression. 6 We review the current literature on the epidemiology, pathophysiology, risk factors, treatment, and surveillance for gynecologic cancer after SOT.
| EPIDEMI OLOGY OF GYNECOLOG I C C ANCERSWe report standardized incidence ratios (SIRs), the ratio of the incidence rate observed among SOT recipients to expected incidence